Files

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest of malignancies, with a dismal survival rate and limited treatment options. Advances in therapeutic modalities are urgently needed not only to successfully restrain tumor growth, but to address the underlying physiological aberrations that drive significant morbidity and mortality in PDAC. Specifically, no therapies exist to treat cachexia, a complex metabolic and behavioral syndrome that is present in up to 85% of patients with PDAC. To address this therapeutic gap, I performed three main studies detailed over the course of this dissertation.

Details

PDF

Statistics

from
to
Export
Download Full History